ExonHit Therapeutics

ExonHit Therapeutics S.A. is a drug and diagnostic discovery company. It focuses on the analysis of alternative RNA splicing, a naturally occurring biological process in which one gene directs the production of several proteins. The company provides data for differential analysis of alternatively spliced transcripts, identifying genes whose splice variants produce abnormal proteins that may contribute to disease development; as well as splice arrays, which are microarrays enabling life science researchers to detect disease-related information. It is also engaged in discovering drugs for neurodegenerative diseases, cancer, and retinal diseases. The company's products include EHT 0202, a small molecule compound that has completed Phase I trials for neurodegenerative and ophthalmic multi-indications; EHT 0101, a preclinical product for treating chronic myeloid leukemia; EHT 0204, a preclinical product for treating ocular neovascular diseases; and EHT 0205, a series of histone deacetylase inhibitors for neurodegenerative diseases and cancer. Additionally, it collaborates with bioMerieux S.A. to develop blood-based cancer diagnostics. The company primarily partners with Allergan, Inc. to identify, develop, and commercialize drugs for neurodegenerative diseases and pain.